Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MOL4239 · 1 trial · 1 indication
he study drug application sites were scored for erythema, induration, and scale assessment using the PSS Scoring system. Psoriasis Severity Score (PSS) Erythema 0 - 4, 0 None, may have residual non-erythematous discoloration 1 Faint erythema 2 Moderate erythema/red color 3 Severe erythema/very red discoloration 4 Very severe erythema/extreme red coloration Induration 0 - 4 0 None 1. Trace or slight elevation of plaque above normal skin level 2. Moderate elevation with rounded or sloped edges to plaque 3. Marked elevation with hard, sharp edges to plaque 4. Very marked elevation with very hard, sharp edges to plaque Scaling 0 - 4 0 None 1. Fine scales 2. Coarse scales 3. Thick scales with a rough surface 4. Thick scales with a very rough surface The scores were summed
| Arm | Type | Description |
|---|---|---|
| 10% MOL4239 ointment & placebo ointment | EXPERIMENTAL | 10% MOL4239 ointment to one target lesion and placebo ointment to the contralateral target lesion twice a day for 28.5 consecutive days |
| Name | Type | Description |
|---|---|---|
| MOL4239 | DRUG | 10% MOL4239 ointment to one target lesion twice a day for 28.5 consecutive days |
| Placebo | DRUG | placebo ointment to the contralateral target lesion twice a day for 28.5 consecutive days |
Inclusion Criteria: * Adults, males or females, 18 to 72 years of age (both inclusive.) * Mild to moderate plaque psoriasis with lesions that in total are no more than 9.9% BSA and with a baseline Psoriasis Severity Score (PSS) of 6 or more. * Identification of bilaterally symmetrical or approximat...
MOL4239 is an investigational small molecule being developed for the treatment of psoriasis, a dermatological condition. It is currently in Phase 2 clinical development and has been studied in a completed clinical trial in the United States.
MOL4239 is being developed by Moleculin Biotech, Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol MBRX. The company is conducting clinical research on this investigational drug for psoriasis.
MOL4239 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to evaluate its safety and efficacy for the treatment of psoriasis.
MOL4239 has been studied in one completed Phase 2 clinical trial with the identifier NCT01826201. The trial, titled "Paired Psoriasis Lesion, Comparative, Study to Evaluate MOL4239 in Psoriasis," enrolled 21 participants in the United States and was completed.
MOL4239 is the primary name used for this investigational drug in clinical development. No alternative names have been reported for this compound in the available clinical trial information.